PharMEDium Healthcare, a portfolio company of Clayton Dubilier & Rice, has filed for an IPO, planning to list on the NYSE under the symbol PMHC. Founded in 2003, the company is a provider of outsourced compounded sterile preparations to acute care hospitals in the U.S. It currently offers over 2,000 SKUs to meet the individual requirements of approximately 3,000 acute care hospital customers that include integrated delivery systems, academic medical centers and general hospital groups. In 2014, PharMEDium generated revenue of $374.1 million and adjusted EBITDA of $96.6 million on a pro forma basis. CD&R initially backed the company in 2014 and holds a nearly 89% ownership interest.